Two latest studies published Tuesday provided additional evidence to support the new controversial cholesterol guidelines that could increase the number of Americans advised to take cholesterol-lowering drugs called statins.

One of the study stated that the new guidelines in a better way can determine who is truly at risk of a heart attack and should be given stations.

The other study suggested that treating people based on the new guidelines would be cost-effective, even if there is tremendous increase in use of statins.

It has been said that the new studies are not large clinical trials that will settle the matter of whether to expand the treatment to millions more people in hopes of preventing cardiovascular disease.

But they could help to lessen the criticism of the new guidelines. It will also strengthen the position of those who argue that the treatment should be extended to more people.

An editorial that came along with the publication of the studies in JAMA, said, “There is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom”.

The editorial was written by Dr. Philip Greenland of Northwestern University, a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.

Dr. Harlan Krumholz, a cardiologist at Yale, affirmed that the studies indicate that the guidelines allow you to treat more people and provide better results at a reasonable cost.